Cardiometabolic comorbidities and life expectancy in people on medication for schizophrenia in Australia

This study aimed to assess the risks of people on medication for schizophrenia developing different components of the metabolic syndrome and their life expectancy, through reference to a representative population of Australians without schizophrenia.

Authors: David J Castle, Eric Chung

Current Medical Research and Opinion https://pubmed.ncbi.nlm.nih.gov/29276845/ | Date: January 8, 2018